Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06353087
Status:
RECRUITING
Last Update Posted:
2024-04-08
First Post:
2024-03-21
Brief Title:
Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis ATTRACT Registry
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
The Real-world Treatment Patterns and Clinical Outcomes in Moderate-to-severe Atopic Dermatitis AD Patients Receiving Abrocitinib
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATTRACT
Brief Summary:
This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period and to describe patient demographic and baseline characteristics
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None